老年晚期非小细胞肺癌免疫检查点抑制剂治疗中国专家共识(2025版)解读OA

With the acceleration of population aging and the extension of life expectancy,there is an increasing demand for anti-tumor therapies among elderly patients with lung cancer.To standardize the clinical application of immunotherapy in elderly patients with lung cancer,Chinese Expert Consensus on Immune Checkpoint Inhibitor Therapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer(Version 2025)has been jointly developed by National Center of Gerontology,the Lung Cancer Committee of Beijing Society of Oncology,and the Editorial Board of the Chinese Journal of Geriatrics.This article interprets key clinical issues addressed in the consensus,including geriatric assessment,selection of immunotherapy regimens,management of immune-related adverse events,and future research directions,to facilitate clinical application.